In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

The Journal of Pharmacology and Experimental Therapeutics
Marc P MaillardMichel Burnier

Abstract

In vitro studies have shown that telmisartan is an insurmountable angiotensin II subtype-1 (AT1) receptor antagonist. Herein, the molecular basis of this insurmountable antagonism has been investigated in vitro, and the effect of telmisartan has been compared in vivo with that of irbesartan and candesartan. Association and dissociation kinetics of telmisartan to AT1 receptors have been characterized in vitro on rat vascular smooth muscle cells (RVSMC) expressing solely the AT1 receptor subtype. In a second set of experiments, the antagonistic efficacy of single intravenous doses (0.1, 0.3, and 1 mg/kg) of telmisartan was compared with that of irbesartan (0.3, 1.0, 3.0, and 10.0 mg/kg) and candesartan (0.3 and 1 mg/kg) in conscious, normotensive, male Wistar rats. The results show that the specific binding of [(3)H]telmisartan to the surface of living RVSMC is saturable and increases quickly to reach equilibrium within 1 h. Telmisartan dissociates very slowly from the receptor with a dissociation half-life (t(1/2)) of 75 min, which is comparable with candesartan and almost 5 times slower than angiotensin II (AngII). In vivo, telmisartan blunts the blood pressure response to exogenous AngII dose dependently. The blockade is long ...Continue Reading

References

Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
Oct 1, 1994·Trends in Pharmacological Sciences·M J RobertsonP Leff
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·H T SchambyeT W Schwartz
Nov 1, 1995·British Journal of Pharmacology·M BurnierE Bürki
Jan 14, 1997·European Journal of Pharmacology·M OjimaK Nishikawa
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Sep 16, 1999·Hypertension Research : Official Journal of the Japanese Society of Hypertension·P B Timmermans
Mar 4, 2000·Lancet·M Burnier, H R Brunner
Nov 15, 2000·Biochemical Pharmacology·P M VanderheydenG Vauquelin
Feb 2, 2002·Clinical Pharmacology and Therapeutics·Marc P MaillardHans R Brunner

❮ Previous
Next ❯

Citations

Dec 21, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kiyo TakeuchiHiromi Rakugi
Sep 2, 2004·Nature Reviews. Drug Discovery·David C Swinney
Apr 12, 2005·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Michael A Weber
Dec 25, 2004·International Journal of Clinical Practice. Supplement·J Z Parra CarrilloM D C García Luna Viesca
Jan 1, 2005·Future Cardiology·Thomas Unger, Michael Schupp
Jan 1, 2010·Integrated Blood Pressure Control·Jean-Philippe BaguetGilles Barone-Rochette
Apr 18, 2014·Vascular Health and Risk Management·Ji-Guang WangFrank Chwallek
Sep 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Toru YamashitaKoji Abe
Feb 16, 2005·Expert Opinion on Drug Safety·Steffen BöhlerWilhelm Kirch
Aug 8, 2012·Clinical and Experimental Hypertension : CHE·Yves Lacourcière
Jul 2, 2011·Current Medical Research and Opinion·Luis M Ruilope
May 23, 2008·Kidney International·George BakrisUNKNOWN AMADEO Study Investigators
Sep 24, 2015·British Journal of Pharmacology·Indira NederpeltLaura H Heitman
Oct 2, 2009·Metabolism: Clinical and Experimental·Gregory AubertAnne Zanchi
Aug 12, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·Naoaki HaradaKenji Okajima
Sep 22, 2006·Molecular and Cellular Endocrinology·David A SchwarzRichard A Maki
Apr 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yusuke FukuiKoji Abe
Dec 24, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Syoichiro KonoKoji Abe
Sep 23, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Tomoko KurataKoji Abe
Sep 24, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Kota SatoKoji Abe
May 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Kota SatoKoji Abe
Jan 18, 2014·Translational Stroke Research·Tomoko KurataKoji Abe
Feb 12, 2010·The Journal of International Medical Research·M Burnier
Dec 4, 2010·Clinical Pediatrics·Albert P Rocchini
Mar 29, 2018·Clinical and Experimental Hypertension : CHE·Di ZhaoPingshuan Dong
May 14, 2005·Expert Review of Cardiovascular Therapy·Marc Maillard, Michel Burnier
Jul 13, 2006·American Journal of Physiology. Endocrinology and Metabolism·Anne ZanchiMichel Burnier
Nov 4, 2006·Expert Review of Cardiovascular Therapy·Matthias GoebelThomas Unger
Mar 22, 2007·American Journal of Physiology. Endocrinology and Metabolism·Anne ZanchiMichel Burnier
Jan 4, 2020·The FEBS Journal·Pyotr A Tyurin-KuzminVsevolod A Tkachuk
Sep 10, 2003·Drugs·Caroline FentonLesley J Scott

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.